Drug-eluting stents

Coronary disease

Lower Rates of In-Stent Thrombosis with the New Generation DES

Original title: New-generation drug-eluting stents reduce stent thrombosis and myocardial infarction: a propensity-score-adjusted analysis from the multicenter REAL...

solaci - 30 October, 2014

Coronary disease

Less Definite Thrombosis with Everolimus Eluting Stents

Original title: Three-Year Outcomes After Revascularization With Everolimus-and Sirulimus -Eluting Stents From the SORT OUT IV Trial. Reference: Lisette Okkels...

solaci - 29 August, 2014

Coronary disease

Direct Implantation of Drug Eluting Stents does not reduce restenosis

Original: Direct drug-eluting Stenting to reduce stent reestenosis (STRESSED). Reference: Wouter S. Remkes et al. J Am Coll Cardiol Intv,...

solaci - 26 August, 2014

Chronic Ischemic cardiopathy

Hemodialysis Associated to Higher Incidence of In Stent Thrombosis

Original title: Impact of hemodialysis on local vessel healing and thrombus formation after drug-eluting stent implantation. Reference: Akihide Konishi, et...

solaci - 8 August, 2014

Acute coronary syndromes

Reduced risk of acute, late and very late thrombosis with new generations of DES versus BMS in the acute myocardial context

Original title: Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from...

solaci - 11 July, 2014

Chronic Ischemic cardiopathy

SYNTAX study final monitoring at 5-years

Original title: Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up...

solaci - 4 July, 2014

Antithrombotic Anticoagulants

3 to 6 months of dual antiplatelet after DES reduced bleeding and did not raise mortality or infarction.

Original title: Meta-analysis of randomized clinical trials comparing short term -vs- long term dual antiplatelet therapy following drug...

solaci - 24 June, 2014

Coronary disease

1-Year Clinical Outcomes of Everolimus-Eluting Bioresorbable Vascular Scaffolds in Diabetic Patients

Original title: 1-Year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds A Pooled Analysis of...

solaci - 10 June, 2014

Lower Rates of In-Stent Thrombosis with the New Generation DES

Less Definite Thrombosis with Everolimus Eluting Stents

Direct Implantation of Drug Eluting Stents does not reduce restenosis

Hemodialysis Associated to Higher Incidence of In Stent Thrombosis

Reduced risk of acute, late and very late thrombosis with new generations of DES versus BMS in the acute myocardial context

SYNTAX study final monitoring at 5-years

3 to 6 months of dual antiplatelet after DES reduced bleeding and did not raise mortality or infarction.

1-Year Clinical Outcomes of Everolimus-Eluting Bioresorbable Vascular Scaffolds in Diabetic Patients

Últimas Noticias

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Noticias Institucionales

Fellow’s Corner 2026 – Submit Your Clinical Case

Watch Again: Cardiovascular Risk Factors in Women | SOLACI Technicians Webinar

Technical Training in Hemodynamics and Interventional Cardioangiology | SOLACI–CACI

Accesos